| enzyme-linked immunosorbent assay for recombinant k39 antigen in diagnosis and prognosis of indian visceral leishmaniasis. | the recombinant product (rk39) of the 39-amino-acid repeats encoded by a kinesin-like protein-encoding gene of leishmania chagasi was evaluated by enzyme-linked immunosorbent assay (elisa) for diagnostic potential and the ability to predict the response to therapy in indian kala-azar or visceral leishmaniasis (vl); we also compared its performance with that of crude soluble antigen (csa). at the diagnosis of vl, the anti-rk39 antibody titer was 59-fold higher than the anti-csa antibody titer. wi ... | 2001 | 11687466 |
| compararative evaluation of rk9, rk26 and rk39 antigens in the serodiagnosis of indian visceral leishmaniasis. | this study was designed for comparative evaluation of two relatively newer recombinant hydrophilic antigens, rk9 and rk26 of leishmania chagasi along with rk39 (a 39-aminoacid-repetitive immunodominant b-cell epitope of kinesin-related antigen from l. chagasi) and crude soluble antigen (csa) for the serodiagnosis of indian visceral leishmaniasis (vl) patients by quantitative elisa. | 2010 | 20212344 |
| generation of luciferase-expressing leishmania infantum chagasi and assessment of miltefosine efficacy in infected hamsters through bioimaging. | the only oral drug available for the treatment of leishmaniasis is miltefosine, described and approved for visceral leishmaniasis in india. miltefosine is under evaluation for the treatment of cutaneous leishmaniasis in the americas although its efficacy for the treatment of human visceral leishmaniasis caused by leishmania infantum chagasi has not been described. drug efficacy for visceral leishmaniasis is ideally tested in hamsters, an experimental model that mimics human disease. luciferase h ... | 2015 | 25679212 |